Gongwin Biopharm Holdings Balance Sheet Health
Financial Health criteria checks 6/6
Gongwin Biopharm Holdings has a total shareholder equity of NT$1.3B and total debt of NT$83.5M, which brings its debt-to-equity ratio to 6.3%. Its total assets and total liabilities are NT$1.5B and NT$226.1M respectively.
Key information
6.3%
Debt to equity ratio
NT$83.46m
Debt
| Interest coverage ratio | n/a |
| Cash | NT$938.38m |
| Equity | NT$1.32b |
| Total liabilities | NT$226.07m |
| Total assets | NT$1.55b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 6617's short term assets (NT$1.1B) exceed its short term liabilities (NT$138.6M).
Long Term Liabilities: 6617's short term assets (NT$1.1B) exceed its long term liabilities (NT$87.4M).
Debt to Equity History and Analysis
Debt Level: 6617 has more cash than its total debt.
Reducing Debt: 6617's debt to equity ratio has reduced from 8.5% to 6.3% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 6617 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: 6617 has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 5.8% each year